SCHEMBL30989850

SCHEMBL30989850

COc1ncc(Cl)cc1C(=O)NC1CCc2ccc(F)cc21

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ PDE10A Q9Y233 6/20 0.51
▸ GPR6 P46095 1/20 0.44
▸ KMT2A Q03164 3/20 0.43
▸ MEN1 O00255 2/20 0.43
▸ TAS1R3 Q7RTX0 1/20 0.42
▸ TAS1R1 Q7RTX1 1/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ CRHR1 P34998 2/20 0.42
▸ HPGDS O60760 1/20 0.41
▸ WDR5 P61964 2/20 0.41
▸ PDE4A P27815 1/20 0.40
▸ PDE4B Q07343 1/20 0.40
▸ PDE4C Q08493 1/20 0.40
▸ PDE4D Q08499 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ RIPK1 Q13546 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30989927 1.00 PDE10A (0.51) PDE10AGPR6KMT2AMEN1TAS1R3
SCHEMBL30990021 0.87 TAS1R3 (0.57) PDE10AKMT2AMEN1TAS1R3TAS1R1
SCHEMBL30989892 0.82 NTRK1 (0.46) GPR6MAPK1CRHR1
SCHEMBL30989853 0.81 PDE4A (0.54) PDE10AKMT2AMEN1TAS1R3TAS1R1
SCHEMBL30989826 0.80 GPR6 (0.39) GPR6CRHR1
SCHEMBL30989846 0.79 GPR6 (0.42) GPR6CRHR1RIPK1
SCHEMBL30989877 0.77 TAS1R3 (0.54) PDE10AKMT2AMEN1TAS1R3TAS1R1
SCHEMBL25237231 0.76 PDE10A (0.44) PDE10AKMT2AMEN1TAS1R3TAS1R1
SCHEMBL30989933 0.75 P2RX7 (0.42) PDE10AGPR6KMT2AMEN1TAS1R3
SCHEMBL30989929 0.75 P2RX7 (0.42) PDE10AGPR6KMT2AMEN1TAS1R3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4612131-A1 NICOTINAMIDE DERIVATIVES FOR USE IN TREATING DISORDERS ASSOCIATED WITH KCNK13 ACTIVITY Cerevance, Inc. (US) 2025-09-10 — — EP disclosed
WO-2024095003-A1 NICOTINAMIDE DERIVATIVES FOR USE IN TREATING DISORDERS ASSOCIATED WITH KCNK13 ACTIVITY Cerevance, Inc. (US) 2024-05-10 — — WO disclosed
Send feedback